Potent antitumor activity of oncolytic adenovirus-mediated SOCS1 for hepatocellular carcinoma

Gene Therapy

Volumn 20, Issue 1, 2013, Pages 84-92

  Liu, L ^a   Li, W ^a   Wei, X ^a   Cui, Q ^a   Lou, W ^a   Wang, G ^a   Hu, X ^a   Qian, C ^a  

^a ZHEJIANG SCI TECH UNIVERSITY   (China)

Author keywords

gene therapy of cancer; hepatocellular carcinoma; oncolytic adenovirus; SOCS1

Indexed keywords

CYCLIN D; MYC PROTEIN; ONCOLYTIC ADENOVIRUS; PROTEIN BCL XL; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SURVIVIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; DNA METHYLATION; DOWN REGULATION; DRUG POTENCY; GENE OVEREXPRESSION; GENE REPLICATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; APOPTOSIS; BCL-X PROTEIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYCLIN D1; DNA METHYLATION; DNA REPLICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HEK293 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; ONCOLYTIC VIRUSES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MYC; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

ADENOVIRIDAE;

EID: 84871997077     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.4     Document Type: Article

References (40)

1. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809
2. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41-51 (Pubitemid 46020826)
3. Devarajan E, Huang S. STAT3 as a central regulator of tumor metastases. Curr Mol Med 2009; 9: 626-633
4. Kim DJ, Chan KS, Sano S, Digiovanni J. Signal transducer and activator of transcription
5. (Stat3) in epithelial carcinogenesis. Mol Carcinogen 2007; 46: 725-731
6. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105 (Pubitemid 38198738)
7. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C et al. Stat3 as an oncogene. Cell 1999; 98: 295-303 (Pubitemid 29380565)
8. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002; 109: 1139-1142 (Pubitemid 34496590)
9. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000; 19: 6613-6626 (Pubitemid 32197700)
10. Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, Sebti SM. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 2005; 24: 3236-3245 (Pubitemid 40695105)
11. Chau MN, Banerjee PP. Development of a STAT3 reporter prostate cancer cell line for high throughput screening of STAT3 activators and inhibitors. Biochem Biophys Res Commun 2008; 377: 627-631
12. Yang L, Ma X, Xiao L, Tang M, Weng X, Sun L et al. Uniquely modified RNA oligonucleotides targeting STAT3 suppress melanoma growth both in vitro and in vivo. Cancer Biol Ther 2009; 8: 2065-2072
13. Wang Y, Ma X, Yan S, Shen S, Zhu H, Gu Y et al. 17-Hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently crosslinking Janus kinases and induces apoptosis of human cancer cells. Cancer Res 2009; 69: 7302-7310
14. Hutzen B, Friedman L, Sobo M, Lin L, Chen L, De Angelis S et al. Curcumin analogue GO-Y030 inhibits STAT3 activity and cell growth in breast and pancreatic carcinomas. Int J Oncol 2009; 35: 867-872
15. Greenhalgh CJ, Miller ME, Hilton DJ, Lund PK. Suppressors of cytokine signaling: relevance to gastrointestinal function and disease. Gastroenterology 2002; 123: 2064-2081 (Pubitemid 35408328)
16. Park Y, Shon SK, Kim A, Kim KI, Yang Y, Cho DH et al. SOCS1 induced by NDRG2 expression negatively regulates STAT3 activation in breast cancer cells. Biochem Biophys Res Commun 2007; 363: 361-367 (Pubitemid 47484341)
17. Ko E, Kim SJ, Joh JW, Park CK, Park J, Kim DH et al. CpG island hypermethylation of SOCS-1 gene is inversely associated with HBV infection in hepatocellular carcinoma. Cancer Lett 2008; 271: 240-250
18. Miyoshi H, Fujie H, Moriya K, Shintani Y, Tsutsumi T, Machuuchi M et al. Methylation status of suppressor of cytokine signaling-1 gene in hepatocellular carcinoma. J Gastroenterol 2004; 39: 563-569 (Pubitemid 38996899)
19. Okochi O, Hibi K, Sakai M, Inoue S, Takeda S, Kaneko T et al. Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. Clin Cancer Res 2003; 9: 5295-5298 (Pubitemid 37413582)
20. Nagai H, Naka T, Terada Y, Komazaki T, Yabe A, Jin E et al. Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas. J Hum Genet 2003; 48: 65-69 (Pubitemid 36305857)
21. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001; 28: 29-35 (Pubitemid 32405812)
22. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006; 130: 1117-1128
23. Flowers LO, Subramaniam PS, Johnson HM. A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells. Oncogene 2005; 24: 2114-2120 (Pubitemid 40516206)
24. Luo J, Xia Q, Zhang R, Lv C, Zhang W, Wang Y et al. Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene. Clin Cancer Res 2008; 14: 2450-2457 (Pubitemid 351551080)
25. Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L et al. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther 2005; 16: 845-858 (Pubitemid 40982333)
26. Pei Z, Chu L, Zou W, Zhang Z, Qiu S, Qi R et al. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 2004; 39: 1371-1381 (Pubitemid 38569059)
27. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002; 2: 103-112 (Pubitemid 41039110)
28. Zhang W, Cai R, Luo R, Wang Y, Cui Q, Wei X et al. The oncolytic adenovirus targeting to TERT and RB pathway induced specific and potent anti-tumor efficacy in vitro and in vivo for hepatocellular carcinoma. Cancer Biol Ther 2007; 6: 1726-1732 (Pubitemid 351590307)
29. Rivera AA, Wang M, Suzuki K, Uil TG, Krasnykh V, Curiel DT et al. Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo. Virology 2004; 320: 121-134 (Pubitemid 38296719)
30. Carette JE, Graat HC, Schagen FH, Abou EL, Hassan MA, van Beusechem VW et al. Replication-dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice-acceptor site. J Gene Med 2005; 7: 1053-1062 (Pubitemid 41195067)
31. Joliot A, Prochiantz A. Transduction peptides: from technology to physiology. Nat Cell Biol 2004; 6: 189-196 (Pubitemid 38344356)
32. Gusarova GA, Wang I, Major ML, Kalinichenko VV, Ackerson T, Petrovic V et al. A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J Clin Invest 2007; 117: 99-111 (Pubitemid 46048457)
33. Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene 2006; 25: 3848-3856 (Pubitemid 43980480)
34. Qian C, Liu XY, Prieto J. Therapy of cancer by cytokines mediated by gene therapy approach. Cell Res 2006; 16: 182-188 (Pubitemid 43247975)
35. Qing C, Lou W, Shen J, Ma L, Yang Z, Liu L et al. Potent antitumor activity in experimental hepatocellular carcinoma by adenovirus-mediated co-expression of TRAIL and shRNA against COX-2. Clin Cancer Res 2010; 16: 3696-3705
36. Penuelas I, Mazzolini G, Boan JF, Sangro B, Marti-Climent J, Ruiz M et al. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology 2005; 128: 1787-1795 (Pubitemid 40824689)
37. Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004; 22: 1389-1397 (Pubitemid 41103620)
38. Cui Q, Jiang W, Wang Y, Lv C, Luo J, zhang W et al. Transfer of suppressor of cytokine signaling 3 by an oncolytic adenovirus induces potential antitumor activities in hepatocellular carcinoma. Hepatology 2008; 47: 105-112 (Pubitemid 351171047)
39. Aghi M, Robert LM. Oncolytic viral therapies-the clinical experience. Oncogene 2005; 24: 7802-7816 (Pubitemid 41670681)
40. Mathis JM, Stoff-Khalili MA, Curiel DT. Oncolytic adenoviruses-selective retargeting to tumor cells. Oncogene 2005; 24: 7775-7791 (Pubitemid 41670679)